Tonix plans phase 2 study of lyme disease prevention drug by 2027

April 29, 2026 7:00 AM

Tonix Pharmaceuticals Holding Corp. (NASDAQ: TNXP) announced plans to initiate a phase 2 field study of TNX-4800, an experimental monoclonal ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

No results found